Details for Patent: 8,663,685

US Patent 8,663,685: Scope, Claims, Expiration, Litigation, and Fampridine Patent Landscape

US Patent 8,663,685 covers a dosing method for improving walking in multiple sclerosis patients using 10 mg of sustained-release 4-aminopyridine, also known as fampridine or dalfampridine, administered orally twice daily. Its dependent claims add pharmacokinetic, release-profile, polymer-matrix, and 12-hour dosing limitations.

The patent was associated with Acorda Therapeutics’ Ampyra product. The Federal Circuit later affirmed invalidity findings against the related sustained-release fampridine patent estate, materially reducing the enforceability of the claims even though the patent remains an important reference for product, litigation, and Orange Book analysis.[1]

What does US Patent 8,663,685 cover?

The patent claims a method of treating a human multiple sclerosis patient rather than the fampridine molecule itself.

Independent claim 1

Claim 1 requires all of the following:

The claim is narrow in dosage and schedule but broad in the identity of the excipients and the precise sustained-release technology. It does not require a particular tablet shape, coating, polymer, dissolution specification, plasma concentration, or walking test.

The claim also does not expressly require the patient to have a particular level of disability, a specific Expanded Disability Status Scale score, or a defined improvement threshold. The phrase “improving walking” creates a clinical-use limitation, which would generally require proof that the claimed regimen is used for the claimed therapeutic purpose.

Dependent claims

Claims 2 through 8 are narrower than claim 1 and are more dependent on technical evidence concerning formulation performance, pharmacokinetics, and manufacturing composition.

How broad is the scope of claim 1?

Claim 1 is a method-of-use claim with a formulation limitation. It does not claim every use of fampridine, every extended-release product, or every multiple sclerosis treatment.

A potentially infringing product or regimen would generally need to satisfy each material limitation:

1. The product contains 4-aminopyridine.
2. The product is administered orally.
3. The dose is 10 mg per administration.
4. Administration occurs twice daily.
5. The dosage form is sustained release.
6. The treatment is used in a human multiple sclerosis patient.
7. Treatment continues for at least two weeks.
8. The treatment is directed to improving walking.

A 10 mg immediate-release product would fall outside the literal scope of claim 1 because the claim requires sustained release. A sustained-release product administered once daily would also fall outside the literal scope because the claim requires twice-daily administration.

A product with a different unit strength could raise infringement issues if the prescribed regimen still delivers 10 mg twice daily, although the analysis would depend on how the product is administered and whether the claim limitations are met. A 20 mg tablet split into two 10 mg doses could present a different analysis from a product designed and labeled for once-daily 20 mg dosing.

What formulations are protected by US Patent 8,663,685?

The patent covers sustained-release formulations at the method-of-use level. Claims 6 and 7 specifically address polymer and matrix systems.

Polymer-controlled formulations

Claim 6 requires that 4-aminopyridine be dispersed in a rate-of-release-controlling polymer. Relevant polymer technologies may include hydrophilic matrix polymers, hydrophobic matrix polymers, or other excipient systems that regulate drug diffusion or erosion.

The claim does not identify a single polymer by name. That gives it broader formulation coverage than a claim limited to a specific hydroxypropyl methylcellulose grade, polymer viscosity, coating composition, or tablet manufacturing process.

Homogeneous matrix formulations

Claim 7 requires a matrix in which the active ingredient is homogeneously dispersed and which controls release. This limitation is more technically specific than claim 6. Evidence may include:

• Formulation composition;
• Cross-sectional or process data;
• Drug-distribution testing;
• Dissolution testing;
• Manufacturing specifications;
• Technical documents submitted in an ANDA.

A formulation can fall within claim 1 without necessarily falling within claims 6 or 7. For example, a coated multiparticulate or osmotic system may satisfy sustained-release requirements while avoiding a homogeneous polymer matrix, depending on the formulation design and claim construction.

What pharmacokinetic limitations do claims 2 and 5 impose?

Claim 2 requires a mean Tmax between approximately two and six hours. Tmax is the time at which the maximum plasma concentration is reached.

Claim 5 requires an average steady-state plasma concentration between approximately 15 and 35 ng/mL. The claim concerns average exposure at steady state rather than a single peak concentration.

These claims introduce evidentiary questions that do not arise to the same extent under claim 1:

• Whether the range applies to a population mean or individual patients;
• Whether the reported value must be measured under fed or fasted conditions;
• Whether steady state must be established using the claimed twice-daily regimen;
• Whether the claimed range is an inherent property of the accused formulation;
• Whether variability among patients removes the formulation from the claim.

For a generic applicant, claims 2 and 5 could require separate pharmacokinetic analysis even if the product is otherwise bioequivalent to Ampyra.

When does US Patent 8,663,685 expire?

The reported nominal expiration date for US Patent 8,663,685 is July 30, 2025, subject to the applicable patent-term calculation and any adjustment recorded by the USPTO or FDA.[2][3]

The patent was issued on March 4, 2014. Its effective life was therefore driven primarily by the earlier nonprovisional filing and priority chain rather than by the issue date.

The expiration date should be distinguished from enforceability. A patent can remain listed or appear in litigation records after a court has held claims invalid.

What is the FDA and Orange Book status of the patent?

Ampyra is an FDA-approved extended-release dalfampridine product indicated to improve walking in adults with multiple sclerosis, as demonstrated by an increase in walking speed.[4]

The FDA-approved product is a 10 mg extended-release tablet administered twice daily, approximately 12 hours apart. The label warns against exceeding the recommended dose because higher exposure increases seizure risk.[4]

The patent estate associated with Ampyra included multiple patents directed to:

• Sustained-release 4-aminopyridine formulations;
• Dosing regimens;
• Pharmacokinetic performance;
• Treatment of walking impairment in multiple sclerosis;
• Tablet and matrix technologies.

The Orange Book is relevant because listed patents can trigger Paragraph IV litigation and a potential 30-month stay of ANDA approval under the Hatch-Waxman Act. Listing, however, does not establish validity or enforceability. The FDA does not adjudicate patent validity.[2]

Which companies challenged the Ampyra patent estate?

Generic companies, including Roxane Laboratories, Actavis-related entities, Mylan, and Apotex, challenged Acorda’s Ampyra patents through ANDA litigation and Paragraph IV certifications.

Acorda brought infringement actions involving, among other patents, US Patent 8,007,826 and US Patent 8,663,685. The litigation focused on whether the claimed sustained-release fampridine methods were patentably distinct from the prior art and whether later-issued claims could be enforced against generic products.[1]

Federal Circuit outcome

In Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., the Federal Circuit affirmed the district court’s invalidity determination concerning claims in Acorda’s fampridine patent estate.[1]

The decision addressed obviousness-type double patenting and the relationship between Acorda’s earlier patent protection and later patents directed to related sustained-release fampridine subject matter. The court’s decision significantly weakened the blocking effect of the asserted patents.

The practical result was that a generic applicant could rely on invalidity findings rather than waiting solely for patent expiration, depending on the specific patent, defendant, and judgment at issue.

How strong is the patent estate for 4-aminopyridine?

The estate was commercially important but legally vulnerable.

Strengths

• The claims mapped closely to the FDA-approved Ampyra regimen.
• The 10 mg twice-daily schedule corresponded to the marketed product.
• Sustained-release requirements narrowed the field against immediate-release products.
• Pharmacokinetic and polymer claims created multiple potential infringement theories.
• The method-of-use claims aligned with the approved indication to improve walking in multiple sclerosis.

Weaknesses

• 4-aminopyridine was an established compound before the Ampyra patents.
• Sustained-release delivery was a central focus of the prior-art analysis.
• The claims were exposed to obviousness challenges based on combining known 4-aminopyridine activity with known modified-release technologies.
• Related patents created obviousness-type double-patenting risk.
• Method claims could be vulnerable where the generic label omitted or carved out the patented indication, although a label closely matching the Ampyra indication increased risk.

The principal value of US 8,663,685 was therefore not molecule exclusivity. Its value was use-specific and formulation-linked protection around a commercially validated regimen.

What generic entry risks exist for dalfampridine?

Dalfampridine is a small molecule, so the relevant competitive pathway is an ANDA for a generic drug, not a biosimilar application.

Generic entry risk arises from four routes:

1. Paragraph IV certification: The applicant alleges that listed patents are invalid, unenforceable, or not infringed.
2. Patent expiration: The applicant waits until the listed patents expire.
3. Successful litigation: A court holds the asserted claims invalid or not infringed.
4. Carve-out or label strategy: The applicant omits a patented indication where permitted by FDA rules.

Because Ampyra’s core dose and indication are stated in the FDA label, a generic label that closely reproduces the approved walking indication can create method-of-use exposure. A carve-out strategy is more difficult where the commercial value of the product depends on the same indication that generated the branded product’s approval.

The invalidity ruling in the Acorda litigation materially increased generic entry prospects. The remaining risk would depend on unasserted or later-expiring formulation patents, regulatory exclusivity, settlement terms, and the individual generic product’s design.

Does Ampyra have biosimilar risk?

No. Ampyra contains dalfampridine, a chemically synthesized small molecule. Competitors enter through the abbreviated new drug application pathway as generic dalfampridine extended-release products.

The relevant risks are:

• Generic substitution;
• ANDA approval timing;
• Paragraph IV litigation;
• Formulation differences;
• Manufacturing and dissolution performance;
• Labeling and indication strategy.

Biosimilar interchangeability, biologic complexity, and biologic manufacturing barriers do not apply.

What manufacturing and intellectual-property barriers remain?

The molecule itself presents limited composition-of-matter protection because 4-aminopyridine was known before Ampyra. The more relevant barriers are formulation and product-performance requirements.

A generic manufacturer must demonstrate that its extended-release product meets FDA requirements for:

• Active ingredient identity and strength;
• Controlled release;
• Bioequivalence;
• Dissolution performance;
• Stability;
• Content uniformity;
• Manufacturing consistency;
• Labeling requirements.

Those requirements can create practical barriers without creating durable patent exclusivity. A formulation that avoids the polymer-matrix limitations of claims 6 and 7 may still need to match the reference product’s release behavior closely enough for FDA approval.

How does US Patent 8,663,685 compare with related Ampyra patents?

The key distinction is that US 8,663,685 is not primarily a composition-of-matter patent. It is a regimen and therapeutic-use patent that depends on the combination of patient population, indication, dose, frequency, and sustained-release dosage form.

What is the commercial exposure from loss of this patent?

The commercial exposure was tied to Ampyra sales and to Acorda’s ability to delay generic competition. Ampyra was Acorda’s principal commercial product and generated hundreds of millions of dollars in annual revenue before generic competition intensified.[5]

Once generic dalfampridine products became available, expected effects included:

• Price erosion;
• Reduced branded prescription volume;
• Pharmacy substitution;
• Lower net sales;
• Greater payer pressure;
• Declining value of remaining patent claims;
• Reduced licensing leverage.

The economic importance of US 8,663,685 was highest before the Federal Circuit’s invalidity ruling and before generic entry. After those events, its value shifted from an exclusionary asset to a litigation and historical patent-landscape reference.

Key Takeaways

• US Patent 8,663,685 claims oral administration of sustained-release 10 mg 4-aminopyridine twice daily for at least two weeks to improve walking in a multiple sclerosis patient.
• Dependent claims cover a two-to-six-hour Tmax, six- to 12-hour release, steady-state plasma concentrations of 15 to 35 ng/mL, polymer dispersion, homogeneous matrix formulations, and 12-hour dosing.
• The patent is closely aligned with the FDA-approved Ampyra regimen.
• Its reported nominal expiration date is July 30, 2025.
• The Federal Circuit affirmed invalidity findings involving Acorda’s related fampridine patent estate, materially reducing enforceability.
• Generic competition proceeds through the ANDA pathway, not the biosimilar pathway.
• The principal remaining technical barriers are bioequivalence, dissolution, controlled-release manufacturing, and indication-specific labeling.
• The patent does not protect the 4-aminopyridine molecule itself.

FAQs About US Patent 8,663,685

Is US Patent 8,663,685 a composition-of-matter patent?

No. It is primarily a method-of-treatment patent with formulation and pharmacokinetic limitations in its dependent claims.

Does a once-daily dalfampridine product infringe claim 1?

A once-daily product would not literally satisfy the twice-daily limitation in claim 1. Infringement would require a separate analysis of product use, prescribing instructions, and potential equivalents.

Does claim 1 require a specific polymer?

No. Claim 1 requires a sustained-release composition containing pharmaceutically acceptable excipients. Claims 6 and 7 add polymer and matrix limitations.

Is a generic dalfampridine product a biosimilar?

No. Dalfampridine is a small molecule. A competing product is reviewed as a generic drug through an ANDA.

Can FDA approval overcome the patent?

No. FDA approval and patent validity are separate issues. FDA approval does not establish that a listed patent is valid or noninfringed.

What is the main design-around strategy for this patent?

Potential strategies include a different dosing schedule, a different dosage strength, an alternative sustained-release architecture, or a formulation that avoids the polymer-matrix limitations. Each strategy must still satisfy FDA bioequivalence and labeling requirements.

References

1. Acorda Therapeutics, Inc. v. Roxane Laboratories, Inc., 903 F.3d 1310 (Fed. Cir. 2018).

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: The Orange Book. FDA.

3. U.S. Patent and Trademark Office. (2014). U.S. Patent No. 8,663,685: Methods of improving walking in a human patient with multiple sclerosis. U.S. Department of Commerce.

4. U.S. Food and Drug Administration. (2023). Ampyra (dalfampridine) extended-release tablets, prescribing information. Acorda Therapeutics, Inc.

5. Acorda Therapeutics, Inc. (2020). Form 10-K annual report. U.S. Securities and Exchange Commission.